Suggested FDA restrictions might curtail access to mifepristone.
D000019:Abortifacient Agents; D000028:Abortion, Induced; D000569:Americas; D001695:Biology; D003695:Delivery of Health Care; D019049:Developed Countries; D011307:Drug Prescriptions; D004703:Endocrine System; D005193:Family Planning Services; D006077:Government Agencies; D006285:Health Planning; D006727:Hormone Antagonists; D006728:Hormones; D015735:Mifepristone; D009656:North America; D009934:Organization and Administration; D009938:Organizations; D010827:Physiology; D014481:United States; D014486:United States Food and Drug Administration; D014492:United States Public Health Service
D000019:Abortifacient Agents; D006727:Hormone Antagonists; D006728:Hormones; D015735:Mifepristone
Abortifacient Agents; Abortion, Drug Induced; Abortion, Induced; Americas; Biology; Developed Countries; Distributional Activities; Endocrine System; Family Planning; Fertility Control, Postconception; Government Agencies; Hormone Antagonists; Hormones; North America; Northern America; Organization And Administration; Organizations; Physiology; Prescriptions; Program Activities; Programs; Ru-486; United States; Usfda; Usphs